Quality Earnings: Schering-Plough Sees Payoff From Pleasing FDA
This article was originally published in RPM Report
Schering-Plough is getting back in good graces with FDA after working through an extensive overhaul of its manufacturing compliance. That will pay off in higher profit margins for the company going forward.
You may also be interested in...
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.